back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-12-05 19:38 Tx date 2024-11-26 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
+1,968,611 vol |
19,370,227 | |
| Filed 2024-12-05 19:37 Tx date 2024-11-26 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
11 - Acquisition or disposition carried out privately
|
-250,000 vol |
0 | |
| Filed 2023-05-10 12:23 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
1,155,000 | |
| Filed 2023-03-14 18:14 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$404,250
+2,021,250 vol $0.20 each |
6,744,776 | |
| Filed 2023-03-14 18:13 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$404,250
+4,042,500 vol $0.10 each |
17,401,616 | |
| Filed 2023-02-01 19:04 Tx date 2023-02-01 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$12,249
+116,666 vol $0.105 each |
13,359,116 | |
| Filed 2023-01-26 18:02 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
655,000 | |
| Filed 2023-01-19 16:53 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$84,923
+943,596 vol $0.09 each |
13,242,450 | |
| Filed 2023-01-03 12:14 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$621,925
+6,219,250 vol $0.10 each |
12,298,854 | |
| Filed 2023-01-03 12:13 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+3,109,625 vol |
4,723,526 | |
| Filed 2023-01-03 12:10 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$621,925
+6,219,250 vol $0.10 each |
||
| Filed 2022-05-27 22:22 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+1,051,151 vol |
1,613,901 | |
| Filed 2022-05-27 22:21 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$378,414
+2,102,303 vol $0.18 each |
6,079,604 | |
| Filed 2021-06-17 11:50 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$130,000
+325,000 vol $0.40 each |
355,000 | |
| Filed 2021-06-07 18:02 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$83,426
+216,693 vol $0.385 each |
3,977,301 | |
| Filed 2021-05-21 22:17 Tx date 2021-05-17 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$5,226
+29,037 vol $0.18 each |
3,760,608 | |
| Filed 2020-08-21 11:50 Tx date 2020-08-18 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$128,644
+714,693 vol $0.18 each |
3,731,571 | |
| Filed 2020-07-30 10:53 Tx date 2020-07-15 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$202,590
+562,750 vol $0.36 each |
562,750 | |
| Filed 2020-07-30 10:52 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-07-30 10:52 Tx date 2020-07-15 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$202,590
+1,125,500 vol $0.18 each |
3,016,878 | |
| Filed 2019-11-22 16:50 Tx date 2019-11-04 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$166,869
+595,963 vol $0.28 each |
1,891,378 | |
| Filed 2019-09-24 12:06 Tx date 2019-09-10 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
16 - Acquisition or disposition under a prospectus exemption
|
$100,000
+250,000 vol $0.40 each |
250,000 | |
| Filed 2019-09-24 12:05 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-12-18 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
30,000 | ||
| Filed 2018-12-18 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,295,415 |